Review | Published:

Human hepatocyte transplantation for liver disease: current status and future perspectives

Pediatric Research volume 83, pages 232240 (2018) | Download Citation

Abstract

Liver transplantation is the accepted treatment for patients with acute liver failure and liver-based metabolic disorders. However, donor organ shortage and lifelong need for immunosuppression are the main limitations to liver transplantation. In addition, loss of the native liver as a target organ for future gene therapy for metabolic disorders limits the futuristic treatment options, resulting in the need for alternative therapeutic strategies. A potential alternative to liver transplantation is allogeneic hepatocyte transplantation. Over the last two decades, hepatocyte transplantation has made the transition from bench to bedside. Standardized techniques have been established for isolation, culture, and cryopreservation of human hepatocytes. Clinical hepatocyte transplantation safety and short-term efficacy have been proven; however, some major hurdles—mainly concerning shortage of donor organs, low cell engraftment, and lack of a long-lasting effect—need to be overcome to widen its clinical applications. Current research is aimed at addressing these problems, with the ultimate goal of increasing hepatocyte transplantation efficacy in clinical applications.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from $8.99

All prices are NET prices.

References

  1. 1.

    , , et al. Hepatocellular transplantation for metabolic deficiencies: decrease of plasma bilirubin in Gunn rats. Science 1976;192:892–894.

  2. 2.

    , , , , . Hepatocellular transplantation in acute liver failure. Surgery 1977;82:124–132.

  3. 3.

    , , , . Intrahepatic transplantation of normal hepatocytes prevents Wilson’s disease in Long-Evans cinnamon rats. Gastroenterology 1996;111:1654–1660.

  4. 4.

    , , , , , . Correction of liver disease by hepatocyte transplantation in a mouse model of progressive familial intrahepatic cholestasis. Gastroenterology 2000;119:1720–1730.

  5. 5.

    , , . Hepatocyte transplantation in man. Transplant Proc 1992;24:3052–3053.

  6. 6.

    , , , , . Clinical hepatocyte transplantation: practical limits and possible solutions. Eur Surg Res 2015;54:162–177.

  7. 7.

    , , et al. One liver for four children: first clinical series of liver cell transplantation for severe neonatal urea cycle defects. Transplantation 2009;87:636–641.

  8. 8.

    , , , , , . Sustained engraftment and tissue enzyme activity after liver cell transplantation for argininosuccinate lyase deficiency. Gastroenterology 2006;130:1317–1323.

  9. 9.

    , , et al. One liver, three recipients: segment IV from split-liver procedures as a source of hepatocytes for cell transplantation. Transplantation 2004;77:1614–1616.

  10. 10.

    , , et al. Hepatocyte transplantation for inherited factor VII deficiency. Transplantation 2004;78:1812–1814.

  11. 11.

    , , et al. Hepatocyte transplantation as a treatment for glycogen storage disease type 1a. Lancet 2002;359:317–318.

  12. 12.

    , , et al. Hepatocyte transplantation in a 4-year-old girl with peroxisomal biogenesis disease: technique, safety, and metabolic follow-up. Transplantation 2003;76:735–738.

  13. 13.

    , , et al. Hepatocyte transplantation using the domino concept in a child with tetrabiopterin nonresponsive phenylketonuria. Cell Transplant 2012;21:2765–2770.

  14. 14.

    , , et al. Liver cell transplantation in severe infantile oxalosis—a potential bridging procedure to orthotopic liver transplantation? Nephrol Dial Transplant 2012;27:2984–2989.

  15. 15.

    , , , . Human fetal hepatocyte transplantation in patients with fulminant hepatic failure. Transplantation 1994;58:951–952.

  16. 16.

    , , et al. Hepatocyte transplantation in acute liver failure. Liver Transpl 2000;6:32–40.

  17. 17.

    , , et al. Peritoneal transplantation of human fetal hepatocytes for the treatment of acute fatty liver of pregnancy: a case report. Trop Gastroenterol 2004;25:141–143.

  18. 18.

    , , et al. Hepatocyte transplantation in an acute liver failure due to mushroom poisoning. Transplantation 2006;82:1115–1116.

  19. 19.

    , , , . Human hepatocyte transplantation: current experience and futurie challenges. Nat Rev Gastroenterol Hepatol 2010;7:288–298.

  20. 20.

    , , et al. Hepatocyte transplantation program: lessons learned and future strategies. World J Gastroenterol. 2016;22:874–886.

  21. 21.

    , , et al. Cryopreservation of human hepatocytes alters the mitochondrial respiratory chain complex 1. Cell Transplant 2007;16:409–419.

  22. 22.

    , , et al. Engraftment assessment in human and mouse liver tissue after sex-mismatched liver cell transplantation by real-time quantitative PCR for Y chromosome sequences. Liver Transpl 2002;8:822–828.

  23. 23.

    , , et al. Neonatal livers: a source for the isolation of good-performing hepatocytes for cell transplantation. Cell Transplant 2014;23:1229–1242.

  24. 24.

    , , et al. Human fetal liver-derived stem cell transplantation as supportive modality in the management of end-stage decompensated liver cirrhosis. Cell Transplant 2010;19:409–418.

  25. 25.

    , , , , , . Domino hepatic transplantation using the liver from a patient with familial amyloid polyneuropathy. Transplantation 1998;65:1496–1498.

  26. 26.

    , . High-yield preparation of isolated rat liver parenchymal cells: a biochemical and fine structural study. J Cell Biol 1969;43:506–520.

  27. 27.

    . Preparation of isolated rat liver cells. Methods Cell Biol 1976;13:29–83.

  28. 28.

    , , et al. Human hepatocyte isolation and relationship of cell viability to early graft function. Cell Transplant 2003;12:69–74.

  29. 29.

    , , , , . Optimization of the cryopreservation and thawing protocol for human hepatocytes for use in cell transplantation. Liver Transplant 2010;16:229–237.

  30. 30.

    , , et al. Rapid and sensitive assessment of human hepatocyte functions. Cell Transplant 2014;23:1545–1556.

  31. 31.

    , , , , . Studies of liver repopulation using the dipeptidyl peptidase IV-deficient rat and other rodent recipients: cell size and structure relationships regulate capacity for increased transplanted hepatocyte mass in the liver lobule. Hepatology 1996;23:482–496.

  32. 32.

    , , , , . Efficacy and safety of repeated hepatocyte transplantation for significant liver repopulation in rodents. Gastroenterology 1996;111:1092–1102.

  33. 33.

    . Clinical human hepatocyte transplantation: current status and challenges. Liver Transplant 2015;21:S39–S44.

  34. 34.

    , , . Hepatocyte transplantation for the treatment of human disease. Semin Liver Dis 1999;19:39–48.

  35. 35.

    , , et al. Alginate microencapsulated hepatocytes optimised for transplantation in acute liver failure. PLoS ONE 2014;9:e113609.

  36. 36.

    , , et al. Transplantation of human hepatocytes. Transplant Proc 1997;29:2103–2106.

  37. 37.

    , , et al. Isolated hepatocyte transplantation in an infant with a severe urea cycle disorder. Pediatrics 2003;111 (6 Pt 1): 1262–1267.

  38. 38.

    , , , , , . Cryopreserved liver cell transplantation controls ornithine transcarbamylase deficient patient while awaiting liver transplantation. Am J Transplant 2005;5:2058–2061.

  39. 39.

    , , et al. Hepatocyte transplantation followed by auxiliary liver transplantation—a novel treatment for ornithine transcarbamylase deficiency. Am J Transpl 2008;8:452–457.

  40. 40.

    , , et al. Host conditioning and rejection monitoring in hepatocyte transplantation in humans. J Hepatol 2017;66:987–1000.

  41. 41.

    , , et al. Treatment of the Crigler–Najjar syndrome type I with hepatocyte transplantation. N Engl J Med 1998;338:1422–1427.

  42. 42.

    , , et al. Isolated hepatocyte transplantation for Crigler-Najjar syndrome type 1. Cell Transplant 2005;14:151–157.

  43. 43.

    , , , , , . Liver cell transplantation for Crigler-Najjar syndrome type I: update and perspectives. World J Gastroenterol 2008;14:3464–3470.

  44. 44.

    , , et al. Hepatocyte transplantation for glycogen storage disease type Ib. Cell Transplant 2007;16:629–637.

  45. 45.

    , , et al. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med 1995;1:1148–1154.

  46. 46.

    , , , , . Quantitation of transplanted hepatic mass necessary to cure the gunn rat model of hyperbilirubinemia. J Pediatr Surg 1992;27:298–301.

  47. 47.

    , . Unusual patterns of alloimmunity evoked by allogeneic liver parenchymal cells. Immunol Rev 2000;174:260–279.

  48. 48.

    , . Antigen-presenting cell function in the tolerogenic liver environment. Nat Rev Immunol 2010;10:753–766.

  49. 49.

    , , , . Immunological aspects of liver cell transplantation. World J Transplant 2016;6:42.

  50. 50.

    , , et al. Entry and integration of transplanted hepatocytes in rat liver plates occur by disruption of hepatic sinusoidal endothelium. Hepatology 1999;29:509–519.

  51. 51.

    , , , , . Early loss of transplanted autologous hepatocytes-lysis by leukocytes in vivo and in vitro. Transplant Proc 2001;33:651–653.

  52. 52.

    , , et al. The instant blood-mediated inflammatory reaction characterized in hepatocyte transplantation. Transplantation 2011;91:632–638.

  53. 53.

    , , , , . Instant blood-mediated inflammatory reaction in hepatocyte transplantation: current status and future perspectives. Cell Transplant 2016;25:1227–1236.

  54. 54.

    , , et al. A functional model of hepatocyte transplantation for in vivo immunologic studies. Transplantation 1998;65:53–61.

  55. 55.

    , , et al. Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I. Nat Genet 1996;12:266–273.

  56. 56.

    , , et al. Spontaneous hepatic repopulation in transgenic mice expressing mutant human α1-antitrypsin by wild-type donor hepatocytes. J Clin Invest 2011;121:1930–1934.

  57. 57.

    . Cell therapy to remove excess copper in Wilson’s disease. Ann N Y Acad Sci 2014;1315:70–80.

  58. 58.

    , , et al. Non-viral FoxM1 gene delivery to hepatocytes enhances liver repopulation. Cell Death Dis 2014;5:e1252.

  59. 59.

    , , et al. De novo donor-specific HLA antibody formation in two patients with Crigler-Najjar Syndrome type I following human hepatocyte transplantation with partial hepatectomy preconditioning. Am J Transplant 2016;16:1021–1030.

  60. 60.

    , , et al. Efficient hepatocyte engraftment in a nonhuman primate model after partial portal vein embolization. Transplantation 2006;82:1067–1073.

  61. 61.

    , , et al. Improving the techniques for human hepatocyte transplantation:Report from a consensus meeting in London. Cell Transplant 2012;21:1–10.

  62. 62.

    , , et al. Liver repopulation by transplanted hepatocytes in a rat model of acute liver failure induced by carbon tetrachloride and a partial hepatectomy. Ann Transpl 2010;15:49–55.

  63. 63.

    , , et al. Correction of liver disease following transplantation of normal rat hepatocytes into Long-Evans Cinnamon rats modeling Wilson’s disease. Mol Ther 2001;3:302–309.

  64. 64.

    . Portal vein embolization (prior to major hepatectomy) effects on regeneration, resectability, and outcome. J Surg Oncol 2010;102:960–967.

  65. 65.

    , , et al. Efficient hepatocyte engraftment and long-term transgene expression after reversible portal embolization in nonhuman primates. Hepatology 2009;49:950–959.

  66. 66.

    , , et al. Improved hepatocyte engraftment after portal vein occlusion in LDL receptor-deficient WHHL rabbits and lentiviral-mediated phenotypic correction in vitro. Cell Med 2012;4:85–98.

  67. 67.

    , , et al. Single liver lobe repopulation with wildtype hepatocytes using regional hepatic irradiation cures jaundice in Gunn rats. PLoS ONE 2012;7:e46775.

  68. 68.

    , , et al. Allospecific CD154+ B cells associate with intestine allograft rejection in children. Transplantation 2010;90:1226–1231.

  69. 69.

    , , et al. Allospecific CD154+ T cells associate with rejection risk after pediatric liver transplantation. Am J Transplant 2009;9:179–191.

  70. 70.

    , , et al. Use of indium-111-labeled hepatocytes to determine the biodistribution of transplanted hepatocytes through portal vein infusion. Clin Nucl Med 2000;25:447–450.

  71. 71.

    , , , , , . Use of a clinically approved iron oxide MRI contrast agent to label human hepatocytes. Cell Transplant 2011;20:963–975.

  72. 72.

    , , , . Preclinical swine models for monitoring of hepatocyte transplantation by MRI. Methods Mol Biol 2017;1506:201–214.

  73. 73.

    , , , , . Engraftment measurement in human liver tissue after liver cell transplantation by short tandem repeats analysis. Cell Transplant 2004;13:231–236.

  74. 74.

    , , et al. Tissue-specific exosome biomarkers for noninvasively monitoring immunologic rejection of transplanted tissue. J Clin Invest 2017;127:1–17.

  75. 75.

    , , et al. Graft-derived cell-free DNA, a noninvasive early rejection and graft damage marker in liver transplantation: a prospective, observational, multicenter cohort study. PLoS Med 2017;14:1–19.

  76. 76.

    , , , . Stem cell therapies for treatment of liver disease. Biomedicines 2016;4:2.

  77. 77.

    , , et al. Adult-derived human liver mesenchymal-like cells as a potential progenitor reservoir of hepatocytes? Cell Transplant 2007;16:717–728.

  78. 78.

    , . Hepatocyte differentiation of mesenchymal stem cells. Hepatobiliary Pancreat Dis Int 2012;11:360–371.

  79. 79.

    , . Anti-inflammatory effects of mesenchymal stem cells: novel concept for future therapies. Expert Opin Biol Ther 2008;8:569–581.

  80. 80.

    , , et al. Co-culture with mesenchymal stem cells results in improved viability and function of human hepatocytes. Cell Transplant 2013;24:1–29.

  81. 81.

    , , , . Hepatocyte-like cells derived from induced pluripotent stem cells. Hepatol Int 2016;11:1–16.

  82. 82.

    , , et al. Phenotypic and functional analyses show stem cell-derived hepatocyte-like cells better mimic fetal rather than adult hepatocytes. J Hepatol 2015;62:581–589.

  83. 83.

    , , , , . The potential of induced pluripotent stem cell derived hepatocytes. J Hepatol 2016;65:182–199.

  84. 84.

    , , et al. Curative ex vivo liver-directed gene therapy in a pig model of hereditary tyrosinemia type 1. Sci Transl Med 2016;8:1–10.

  85. 85.

    , , , . Alginate encapsulation of human hepatocytes and assessment of microbeads. Methods Mol Biol 2017: 273–281.

  86. 86.

    , , et al. Cryopreservation of hepatocyte microbeads for clinical transplantation. Cell Transplant 2017;26:1341–1354.

Download references

Author information

Affiliations

  1. DhawanLab, Paediatric Liver GI and Nutrition Center and MowatLabs, Institute of Liver Studies, King’s College London, Faculty of Life Sciences and Medicine, King’s College London, King’s College Hospital, London, UK

    • V Iansante
    • , R R Mitry
    • , C Filippi
    • , E Fitzpatrick
    •  & A Dhawan

Authors

  1. Search for V Iansante in:

  2. Search for R R Mitry in:

  3. Search for C Filippi in:

  4. Search for E Fitzpatrick in:

  5. Search for A Dhawan in:

Competing interests

The authors declare no conflict of interest.

Corresponding author

Correspondence to A Dhawan.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/pr.2017.284

STATEMENT OF FINANCIAL SUPPORT

The authors acknowledge “MowatLabs” for financial support.